Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

₹ 1,937 -0.19%
22 Aug - close price
About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Key Points

Leadership[1]

<h1>14th largest and fastest growing in the Indian market</h1> <h1>15th largest generic company by prescriptions filled in the USA</h1> <h1>5th largest Indian generic co. in Europe.</h1>
  • Market Cap 54,671 Cr.
  • Current Price 1,937
  • High / Low 2,286 / 1,275
  • Stock P/E 41.0
  • Book Value 314
  • Dividend Yield 0.13 %
  • ROCE 19.4 %
  • ROE 15.8 %
  • Face Value 1.00

Pros

  • Company's working capital requirements have reduced from 61.2 days to 44.5 days

Cons

  • Stock is trading at 6.18 times its book value
  • The company has delivered a poor sales growth of 4.60% over past five years.
  • Company has a low return on equity of -9.94% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
2,777 3,018 3,100 3,001 3,036 3,207 2,507 3,063 3,244 3,434 3,388 3,256 3,264
2,346 2,539 2,626 2,603 2,599 2,745 2,715 2,559 2,656 2,832 2,787 2,695 2,684
Operating Profit 432 479 474 398 437 462 -209 504 588 602 600 561 581
OPM % 16% 16% 15% 13% 14% 14% -8% 16% 18% 18% 18% 17% 18%
183 86 209 -696 -32 -205 87 351 31 39 31 -361 -297
Interest 60 83 97 109 112 121 134 149 40 48 52 67 58
Depreciation 147 146 152 135 142 141 147 151 118 120 123 125 130
Profit before tax 408 337 435 -542 151 -6 -403 555 462 473 456 8 96
Tax % 48% 17% 33% -26% -14% 997% -18% 319% 26% 25% 24% 45% 51%
211 279 291 -403 173 -62 -331 -1,214 340 354 348 4 47
EPS in Rs 6.82 9.23 9.66 -15.18 5.31 -2.90 -12.45 -43.17 12.06 12.55 12.33 0.16 1.66
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
6,005 6,563 7,562 9,079 9,074 9,865 10,641 10,944 12,305 11,583 11,813 13,322 13,342
4,914 5,348 6,125 7,043 7,457 8,280 8,942 8,860 9,978 9,948 10,618 10,970 10,998
Operating Profit 1,091 1,214 1,437 2,037 1,617 1,586 1,699 2,084 2,327 1,635 1,195 2,351 2,344
OPM % 18% 18% 19% 22% 18% 16% 16% 19% 19% 14% 10% 18% 18%
11 -180 20 -44 89 375 191 95 -101 -10 336 -259 -587
Interest 189 190 179 237 286 335 377 353 298 349 516 207 226
Depreciation 217 300 234 264 302 326 417 444 487 569 582 486 498
Profit before tax 697 544 1,044 1,491 1,119 1,301 1,096 1,382 1,441 707 434 1,399 1,032
Tax % 22% 61% 29% 26% 28% 29% 29% 30% 31% 47% 430% 25%
546 209 743 1,109 804 925 776 970 994 377 -1,434 1,047 754
EPS in Rs 19.99 7.72 26.33 39.29 28.49 32.78 27.50 34.38 33.37 10.53 -53.22 37.11 26.70
Dividend Payout % 0% 26% 8% 5% 7% 6% 9% 7% 7% 24% -5% 7%
Compounded Sales Growth
10 Years: 7%
5 Years: 5%
3 Years: 3%
TTM: 11%
Compounded Profit Growth
10 Years: 17%
5 Years: 12%
3 Years: 6%
TTM: 159%
Stock Price CAGR
10 Years: 5%
5 Years: 32%
3 Years: 72%
1 Year: 15%
Return on Equity
10 Years: 6%
5 Years: -1%
3 Years: -10%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 27 27 28 28 28 28 28 28 28 28 28 28
Reserves 2,956 1,756 3,601 4,464 5,135 5,577 6,042 7,036 9,058 9,446 7,820 8,821
3,267 3,800 3,988 4,724 4,639 4,449 4,869 4,986 3,962 4,608 1,231 2,473
2,176 2,726 2,575 2,548 2,793 3,235 3,729 3,524 4,003 5,289 5,279 4,727
Total Liabilities 8,427 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 16,050
3,091 2,015 2,594 2,755 3,030 3,670 5,029 5,129 5,887 5,422 4,210 4,780
CWIP 5 477 543 708 1,122 1,399 1,222 1,382 1,010 1,190 662 542
Investments 0 17 17 16 15 30 25 25 50 45 790 56
5,331 5,799 7,039 8,285 8,429 8,190 8,393 9,040 10,105 12,715 8,697 10,672
Total Assets 8,427 8,309 10,193 11,764 12,595 13,289 14,668 15,575 17,052 19,371 14,358 16,050

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
854 482 345 657 1,648 1,324 1,392 1,131 1,109 625 -265 -828
-566 -712 -950 -1,001 -1,003 -883 -774 -662 -316 -515 4,387 2
-98 199 699 543 -468 -739 -445 -442 -520 -77 -3,906 787
Net Cash Flow 190 -31 93 199 177 -297 174 28 272 32 215 -38

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 131 140 120 97 94 81 83 86 92 115 57 92
Inventory Days 191 247 249 299 244 244 211 230 208 203 208 254
Days Payable 279 379 308 243 225 241 210 226 190 172 210 216
Cash Conversion Cycle 43 8 61 152 113 85 84 90 110 147 56 129
Working Capital Days 62 47 51 125 99 64 54 67 65 141 -2 44
ROCE % 15% 16% 19% 21% 15% 15% 14% 15% 16% 10% 12% 19%

Shareholding Pattern

Numbers in percentages

3 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.64%
23.14% 23.19% 22.47% 25.51% 24.79% 23.71% 21.38% 20.98% 23.05% 23.51% 23.15% 20.62%
10.90% 10.69% 10.40% 9.10% 10.31% 10.92% 13.36% 13.93% 13.21% 13.85% 14.60% 17.64%
0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04% 0.04%
19.27% 19.45% 20.46% 18.70% 18.21% 18.70% 18.58% 18.42% 17.06% 15.96% 15.56% 15.05%
No. of Shareholders 3,13,5403,00,1062,85,4612,36,9082,32,6852,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,210

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls